Publications and communications of Yves Henrotin

Raman, R., Bahri, M. A., Degueldre, C., Caetano da Silva, C., Sanchez, C., Ostertag, A., Collet, C., Cohen-Solal, M., Plenevaux, A., Henrotin, Y., & Muller, M. (14 January 2024). A Zebrafish Mutant in the Extracellular Matrix Protein Gene efemp1 as a Model for Spinal Osteoarthritis. Animals, 14 (1), 74. doi:10.3390/ani14010074

Henrotin, Y., Herman, J., Uebelhoer, M., Wauquier, F., Boutin-Wittrant, L., Donneau, A.-F., Monseur, J., Fotso, V. M., Duquenne, M., Wagner, M., Bouvret, E., Costes, B., & Wittrant, Y. (21 September 2023). Oral supplementation with fish cartilage hydrolysate in an adult population suffering from knee pain and function discomfort: results from an innovative approach combining an exploratory clinical study and an ex vivo clinical investigation. BMC Musculoskeletal Disorders, 24 (1), 748. doi:10.1186/s12891-023-06800-4

Zappia, J., Tong, Q., Van der Cruyssen, R., Cornelis, F. M. F., Lambert, C., Pinto Coelho, T., Grisart, J., Kague, E., Lories, R. J., Muller, M., Elewaut, D., Hammond, C. L., Sanchez, C., & Henrotin, Y. (20 September 2023). Osteomodulin downregulation is associated with osteoarthritis development. Bone Research, 11 (1), 49. doi:10.1038/s41413-023-00286-5

Gérain, J., Uebelhoer, M., Costes, B., Herman, J., Pietri, S., Donneau, A.-F., Monseur, J., & Henrotin, Y. (22 June 2023). NASAFYTOL® supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial. Frontiers in Nutrition, 10. doi:10.3389/fnut.2023.1137407

Lawford, B. J., Master, H., Larsen, J. B., Bartholdy, C., Corrigan, P., Ginnerup-Nielsen, E., Le, C., Teoli, A., Bennell, K. L., Metcalf, B., Hinman, R. S., Button, K., Collins, N. J., Cottrell, E., Henrotin, Y., Skou, S. T., Thoma, L. M., Wellsandt, E., White, D. K., & Holden, M. A. (2023). What should a toolkit to aid the delivery of therapeutic exercise for hip and knee osteoarthritis look like? Qualitative analysis of an international survey of 318 researchers, clinicians, and consumers by the OARSI Rehabilitation Discussion Group. Musculoskeletal Care. doi:10.1002/msc.1732

Henrotin, Y., Szekanecz, Z., & Masuko, K. (2023). Editorial: Reviews in rheumatology. Frontiers in Medicine, 10, 1153419. doi:10.3389/fmed.2023.1153419

Im, G.-I., & Henrotin, Y. (2023). Regenerative medicine for early osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 15, 1759720X231194813. doi:10.1177/1759720X231194813

Uebelhoer, M., Lambert, C., Grisart, J., Guse, K., Plutizki, S., & Henrotin, Y. (2023). Interleukins, growth factors, and transcription factors are key targets for gene therapy in osteoarthritis: A scoping review. Frontiers in Medicine, 10, 1148623. doi:10.3389/fmed.2023.1148623

Henrotin, Y., Dierckxsens, Y., Delisse, G., Maes, N., & Albert, A. (December 2022). Curcuma longa and Boswellia serrata extract combination for hand osteoarthritis: an open-label pre-post trial. Pharmaceutical Biology, 60 (1), 2295 - 2299. doi:10.1080/13880209.2022.2147550

Conrozier, T., Diraçoglù, D., Monfort, J., Chevalier, X., Bard, H., Baron, D., Jerosch, J., Migliore, A., Richette, P., & Henrotin, Y. (2022). EUROVISCO Good Practice Recommendations for a First Viscosupplementation in Patients with Knee Osteoarthritis. Cartilage, 19476035221138958. doi:10.1177/19476035221138958

Holden, M. A., Metcalf, B., Lawford, B. J., Hinman, R. S., Boyd, M., Button, K., Collins, N. J., Cottrell, E., Henrotin, Y., Larsen, J. B., Master, H., Skou, S. T., Thoma, L. M., Rydz, R., Wellsandt, E., White, D. K., & Bennell, K. (2022). Recommendations for the delivery of therapeutic exercise for people with knee and/or hip osteoarthritis. An international consensus study from the OARSI Rehabilitation Discussion Group. Osteoarthritis and Cartilage. doi:10.1016/j.joca.2022.10.009

Henrotin, Y., Michlmayr, C., Rau, S. M., Quirke, A.-M., Bigoni, M., & Ueberall, M. A. (October 2022). Combination of Enzymes and Rutin to Manage Osteoarthritis Symptoms: Lessons from a Narrative Review of the Literature. Rheumatology and Therapy, 9 (5), 1305 - 1327. doi:10.1007/s40744-022-00472-7

Sanchez, C., Zappia, J., Lambert, C., FOGUENNE, J., Dierckxsens, Y., Dubuc, J.-E., Delcour, J.-P., Gothot, A., & Henrotin, Y. (11 August 2022). Curcuma longa and Boswellia serrata Extracts Modulate Different and Complementary Pathways on Human Chondrocytes In Vitro: Deciphering of a Transcriptomic Study. Frontiers in Pharmacology, 13. doi:10.3389/fphar.2022.931914

Henrotin, Y., Cozannet, R. L., Fança-Berthon, P., Truillet, R., Cohen-Solhal, M., DunnGalvin, G., Grouin, J.-M., & Doolan, A. (07 July 2022). Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial. BMC Musculoskeletal Disorders, 23 (1), 650. doi:10.1186/s12891-022-05612-2

Angelini, F., Widera, P., Mobasheri, A., Blair, J., Struglics, A., Uebelhoer, M., Henrotin, Y., Marijnissen, A. C., Kloppenburg, M., Blanco, F. J., Haugen, I. K., Berenbaum, F., Ladel, C., Larkin, J., Bay-Jensen, A. C., & Bacardit, J. (2022). Osteoarthritis endotype discovery via clustering of biochemical marker data. Annals of the Rheumatic Diseases, 81 (5), 666-675. doi:10.1136/annrheumdis-2021-221763

Henrotin, Y. (2022). Osteoarthritis in year 2021: biochemical markers. Osteoarthritis and Cartilage, 30 (2), 237-248. doi:10.1016/j.joca.2021.11.001

Horcajada, M.-N., Beaumont, M., Sauvageot, N., Poquet, L., Saboundjian, M., Costes, B., Verdonk, P., Brands, G., Brasseur, J., Urbin-Choffray, D., Vandenberghe, M., Brabants, K., De Vlam, K., Fache, W., Jandrain, B., Grek, V., MALAISE, M., & Henrotin, Y. (2022). An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis. Therapeutic Advances in Musculoskeletal Disease, 14, 1759720X211070205. doi:10.1177/1759720X211070205

Sanchez, C., Lambert, C., Dubuc, J.-E., Bertrand, J., Pap, T., & Henrotin, Y. (20 December 2021). Syndecan-4 is Increased in Osteoarthritic Knee, but not Hip or Shoulder, Articular Hypertrophic Chondrocytes. Cartilage, 13 (Issue 2_suppl), 862S-871. doi:10.1177/1947603519870855

Sanchez, C., Hemmer, K., Krömmelbein, N., Seilheimer, B., Dubuc, J.-E., Antoine, C., & Henrotin, Y. (11 May 2021). Reduction of Matrix Metallopeptidase 13 and Promotion of Chondrogenesis by Zeel T in Primary Human Osteoarthritic Chondrocytes. Frontiers in Pharmacology, 12, 1-12. doi:10.3389/fphar.2021.635034

Conrozier, T., Raman, R., Chevalier, X., Henrotin, Y., Monfort, J., Diraçoglù, D., Bard, H., Baron, D., Jerosch, J., Richette, P., & Migliore, A. (2021). Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group. Therapeutic Advances in Musculoskeletal Disease, 13. doi:10.1177/1759720X211018605

Henrotin, Y., Antoine, C., Zwerts, E., Neutelings, T., & Bouvret, E. (2021). Oral supplementation with fish cartilage hydrolysate accelerates joint function recovery in rat model of traumatic knee osteoarthritis. Food Science and Nutrition, 9 (6), 2877-2885. doi:10.1002/fsn3.2244

Henrotin, Y., Tits, C., Paul, J., Gramme, P., Helleputte, T., Migliore, A., Richette, P., Chevalier, X., Monfort, J., Diracoglu, D., Bard, H., Jerosch, J., Baron, D., Raghu, R., & Conrozier, T. (2021). Retreatment with Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis: Agreement between EUROVISCO Guidelines and Current Medical Practice. Cartilage, 19476035211053827. doi:10.1177/19476035211053827

Hick, A.-C., Malaise, M., Loeuille, D., Conrozier, T., Maugars, Y., Pelousse, F., Tits, C., & Henrotin, Y. (2021). Cartilage Biomarkers Coll2-1 and Coll2-1NO2 Are Associated with Knee OA MRI Features and Are Helpful in Identifying Patients at Risk of Disease Worsening. Cartilage. doi:10.1177/19476035211021892

Holden, M. A., Button, K., Collins, N. J., Henrotin, Y., Hinman, R. S., Larsen, J. B., Metcalf, B., Master, H., Skou, S. T., Thoma, L. M., Wellsandt, E., White, D. K., & Bennell, K. (2021). Guidance for Implementing Best Practice Therapeutic Exercise for Patients With Knee and Hip Osteoarthritis: What Does the Current Evidence Base Tell Us? Arthritis Care and Research, 73 (12), 1746-1753. doi:10.1002/acr.24434

L'Hote, C., Cordier, B., Labasse, A., Boileau, C., Costes, B., & Henrotin, Y. (2021). Identification of new biomarkers for sarcopenia and characterization of cathepsin D biomarker. JCSM Rapid Communications, 4, 122-132. doi:10.1002/rco2.26

Lambert, C., Bellemère, G., Boyer, G., Ponelle, F., Bauer, T., Legeny, M.-C., Baudouin, C., & Henrotin, Y. (2021). Composition Analysis and Pharmacological Activity of Avocado/Soybean Unsaponifiable Products Used in the Treatment of Osteoarthritis. Frontiers in Pharmacology, 12, 781389. doi:10.3389/fphar.2021.781389

Lambert, C., Zappia, J., Sanchez, C., Florin, A., Dubuc, J.-E., & Henrotin, Y. (2021). The Damage-Associated Molecular Patterns (DAMPs) as Potential Targets to Treat Osteoarthritis: Perspectives From a Review of the Literature. Frontiers in Medicine, 7, 607186. doi:10.3389/fmed.2020.607186

Mobasheri, A., Fonseca, J. E., Gualillo, O., Henrotin, Y., Largo, R., Herrero-Beaumont, G., & Rocha, F. A. C. (2021). Editorial: Inflammation and Biomarkers in Osteoarthritis. Frontiers in Medicine, 8, 727700. doi:10.3389/fmed.2021.727700

Florin, A., Lambert, C., Sanchez, C., Zappia, J., Durieux, N., Tieppo, A. M., Mobasheri, A., & Henrotin, Y. (2020). The secretome of skeletal muscle cells: A systematic review. Osteoarthritis and Cartilage Open. doi:10.1016/j.ocarto.2019.100019

Batshon, G., Elayyan, J., Qiq, O., Reich, E., Ben-Aderet, L., Kandel, L., Haze, A., Steinmeyer, J., Lefebvre, V., Zhang, H., Elisseeff, J., Henrotin, Y., Mobasheri, A., & Dvir-Ginzberg, M. (2020). Serum NT/CT SIRT1 ratio reflects early osteoarthritis and chondrosenescence. Annals of the Rheumatic Diseases, 79 (10), 1370-1380. doi:10.1136/annrheumdis-2020-217072

Henrotin, Y., Dierckxsens, Y., Delisse, G., SEIDEL, L., & Albert, A. (2020). Curcuminoids and Boswellia serrata extracts combination decreases tendinopathy symptoms: findings from an open-label post-observational study. Current Medical Research and Opinion, 1-20. doi:10.1080/03007995.2020.1860923

Montjean, R., Escaich, S., Paolini, R., Carelli, C., Pirson, S., Neutelings, T., Henrotin, Y., & Vêtu, C. (2020). REG-O3 chimeric peptide combining growth hormone and somatostatin sequences improves joint function and prevents cartilage degradation in rat model of traumatic knee osteoarthritis. PLoS ONE, 15 (4), 0231240. doi:10.1371/journal.pone.0231240

Zappia, J., Joiret, M., Sanchez, C., Lambert, C., Geris, L., Muller, M., & Henrotin, Y. (2020). From translation to protein degradation as mechanisms for regulating biological functions: A review on the SLRP family in skeletal tissues. Biomolecules, 10, 80. doi:10.3390/biom10010080

Henrotin, Y. (February 2019). Les nouveaux biomarqueurs de l'arthrose. Lettre du Rhumatologue, 449, 16-19.

Boisson, M., Borderie, D., Henrotin, Y., Teboul-Coré, S., Lefèvre-Colau, M.-M., Rannou, F., & Nguyen, C. (2019). Serum biomarkers in people with chronic low back pain and Modic 1 changes: a case-control study. Scientific Reports, 9 (1). doi:10.1038/s41598-019-46508-x

de Visser, H. M., Sanchez, C., Mastbergen, S. C., Lafeber, F. P. J. G., Henrotin, Y., & Weinans, H. (2019). Fib3-3 as a Biomarker for Osteoarthritis in a Rat Model with Metabolic Dysregulation. Cartilage, 10 (3), 329-334. doi:10.1177/1947603518754629

Elango, J., Saravanakumar, K., Rahman, S. U., Henrotin, Y., Regenstein, J. M., Wu, W., & Bao, B. (2019). Chitosan-collagen 3d matrix mimics trabecular bone and regulates rankl-mediated paracrine cues of differentiated osteoblast and mesenchymal stem cells for bone marrow macrophage-derived osteoclastogenesis. Biomolecules, 9 (5). doi:10.3390/biom9050173

Henrotin, Y., Bannuru, R., Malaise, M., Ea, H.-K., Confavreux, C., Bentin, J., Urbin-Choffray, D., Conrozier, T., Brasseur, J.-P., Thomas, P., Hick, A.-C., Marinello, A., Giordan, N., & Richette, P. (2019). Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: Data from MOKHA study. BMC Musculoskeletal Disorders, 20 (1). doi:10.1186/s12891-019-2667-0

Henrotin, Y., Malaise, M., Wittoek, R., De Vlam, K., Brasseur, J.-P., Luyten, F. P., Jiangang, Q., Van Den Berghe, M., Uhoda, R., Bentin, J., De Vroey, T., Erpicum, L., Donneau, A.-F., & Dierckxsens, Y. (2019). Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: A double-blind multicenter randomized placebo controlled three-arm study. Arthritis Research and Therapy, 21 (1). doi:10.1186/s13075-019-1960-5

Henrotin, Y., Patrier, S., Pralus, A., Roche, M., & Nivoliez, A. (2019). Protective Actions of Oral Administration of Bifidobacterium longum CBi0703 in Spontaneous Osteoarthritis in Dunkin Hartley Guinea Pig Model. Cartilage. doi:10.1177/1947603519841674

Hick, A.-C., Fonck, M., Costes, B., Cobraiville, E., Pirson, S., Garcia, L., Labasse, A., Vander Poelen, S., & Henrotin, Y. (2019). Serum Levels of Coll2-1, a Specific Biomarker of Cartilage Degradation, Are Not Affected by Sampling Conditions, Circadian Rhythm, and Seasonality. Cartilage, 1947603519878489. doi:10.1177/1947603519878489

Lambert, C., Borderie, D., Dubuc, J.-E., Rannou, F., & Henrotin, Y. (2019). Type II collagen peptide Coll2-1 is an actor of synovitis. Osteoarthritis and Cartilage, 27 (11), 1680-1691. doi:10.1016/j.joca.2019.07.009

Mobasheri, A., Lambert, C., & Henrotin, Y. (2019). Coll2-1 and Coll2-1NO2 as exemplars of collagen extracellular matrix turnover–biomarkers to facilitate the treatment of osteoarthritis? Expert Review of Molecular Diagnostics, 19 (9), 803-812. doi:10.1080/14737159.2019.1646641

Mobasheri, A., van Spil, W. E., Budd, E., Uzieliene, I., Bernotiene, E., Bay-Jensen, A.-C., Larkin, J., Levesque, M. C., Gualillo, O., & Henrotin, Y. (2019). Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Current Opinion in Rheumatology, 31 (1), 80-89. doi:10.1097/BOR.0000000000000567

Legrand, C., Ahmed, U., Anwar, A., Rajpoot, K., Pasha, S., Lambert, C., Davidson, R. K., Clark, I. M., Thornalley, P. J., Henrotin, Y., & Rabbani, N. (June 2018). Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo. Arthritis Research and Therapy, 20 (1), 131. doi:10.1186/s13075-018-1636-6

Conrozier, T., Monfort, J., Chevalier, X., Raman, R., Richette, P., Diraçoglù, D., Bard, H., Baron, D., Jerosch, J., Migliore, A., & Henrotin, Y. (2018). EUROVISCO Recommendations for Optimizing the Clinical Results of Viscosupplementation in Osteoarthritis. Cartilage. doi:10.1177/1947603518783455

Elango, J., Lee, J., Wang, S., Henrotin, Y., De Val, J. E. M. S., Regenstein, J. M., Lim, S. Y., Bao, B., & Wu, W. (2018). Evaluation of differentiated bone cells proliferation by blue shark skin collagen via biochemical for bone tissue engineering. Marine Drugs, 16 (10), 350. doi:10.3390/md16100350

Elango, J., Sanchez, C., de Val, J. E. M. S., Henrotin, Y., Wang, S., Motaung, K. S. C. M., Guo, R., Wang, C., Robinson, J., Regenstein, J. M., Bao, B., & Wu, W. (2018). Cross-talk between primary osteocytes and bone marrow macrophages for osteoclastogenesis upon collagen treatment. Scientific Reports, 8 (1), 5318. doi:10.1038/s41598-018-23532-x

Henrotin, Y. (2018). Avocado/Soybean Unsaponifiables (Piacledine®300) show beneficial effect on the metabolism of osteoarthritic cartilage, synovium and subchondral bone: An overview of the mechanisms. AIMS Medical Science, 5 (1), 33-52.

Henrotin, Y. (2018). Avancées de la recherche sur les marqueurs biologiques de l'arthrose. Bulletin de l'Académie Nationale de Médecine, 202 (1-2), 173-181. doi:10.1016/s0001-4079(19)30349-8

Henrotin, Y., Chevalier, X., Raman, R. N., Richette, P., Montfort, J., Jerosch, J. G., Baron, D., Bard, H., Carrillon, Y., Migliore, A., & Conrozier, T. (2018). EUROVISCO Guidelines for the Design and Conduct of Clinical Trials Assessing the Disease-Modifying Effect of Knee Viscosupplementation. Cartilage. doi:10.1177/1947603518783521

Henrotin, Y., & Mobasheri, A. (2018). Natural Products for Promoting Joint Health and Managing Osteoarthritis. Current Rheumatology Reports, 20 (11), 72. doi:10.1007/s11926-018-0782-9

Raman, R. N., Henrotin, Y., Chevalier, X., Migliore, A., Jerosch, J., Montfort, J., Bard, H., Baron, D., Richette, P., & Conrozier, T. (2018). Decision Algorithms for the Retreatment with Viscosupplementation in Patients Suffering from Knee Osteoarthritis: Recommendations from the EUROpean VIScosupplementation COnsensus Group (EUROVISCO). Cartilage. doi:10.1177/1947603517693043

Sanchez, C., Mazzucchelli, G., Lambert, C., Comblain, F., De Pauw, E., & Henrotin, Y. (2018). Comparison of secretome from osteoblasts derived from sclerotic versus non-sclerotic subchondral bone in OA: A pilot study. PLoS ONE, 13 (3), 0194591. doi:10.1371/journal.pone.0194591

Tavasolian, F., Abdollahi, E., Rezaei, R., Momtazi-borojeni, A. A., Henrotin, Y., & Sahebkar, A. (2018). Altered Expression of MicroRNAs in Rheumatoid Arthritis. Journal of Cellular Biochemistry, 119 (1), 478-487. doi:10.1002/jcb.26205

Sanchez, C., Bay-Jensen, A.-C., Pap, T., Dvir-Ginzberg, M., Quasnichka, H., Barrett-Jolley, R., Mobasheri, A., & Henrotin, Y. (August 2017). Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. Osteoarthritis and Cartilage, 25, 1199-1209. doi:10.1016/j.joca.2017.02.797

Demoulin, C., Depas, Y., Vanderthommen, M., Henrotin, Y., Wolfs, S., Cagnie, B., & Hidalgo, B. (March 2017). LA THÉRAPIE MANUELLE ORTHOPÉDIQUE : définition, caractéristiques et mise au point sur la situation en Belgique. Revue Médicale de Liège, 72 (3), 126-131.

Bartels, E. M., Henrotin, Y., Bliddal, H., Centonze, P., & Henriksen, M. (2017). Relationship between weight loss in obese knee osteoarthritis patients and serum biomarkers of cartilage breakdown: secondary analyses of a randomised trial. Osteoarthritis and Cartilage, 25 (10), 1641-1646. doi:10.1016/j.joca.2017.06.009

Comblain, F., Barthelemy, N., Lefebvre, M., Schwartz, C., Lesponne, I., Serisier, S., Feugier, A., Balligand, M., & Henrotin, Y. (2017). A randomized, double-blind, prospective, placebo-controlled study of the efficacy of a diet supplemented with curcuminoids extract, hydrolyzed collagen and green tea extract in owner's dogs with osteoarthritis. BMC Veterinary Research, 13, 395. doi:10.1186/s12917-017-1317-8

Comblain, F., Rocasalbas, G., Gautier, S., & Henrotin, Y. (2017). Chitosan : a promising polymer for cartilage repair and viscosupplementation. Bio-medical Materials and Engineering. doi:10.3233/BME-171643

Elayyan, J., Lee, E.-J., Gabay, O., Smith, C. A., Qiq, O., Reich, E., Mobasheri, A., Henrotin, Y., Kimber, S. J., & Dvir-Ginzberg, M. (2017). LEF1-mediated MMP13 gene expression is repressed by SIRT1 in human chondrocytes. FASEB Journal. doi:10.1096/fj.201601253R

Henrotin, Y., Berenbaum, F., Chevalier, X., Marty, M., Richette, P., & Rannou, F. (2017). Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: The EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial. BMC Musculoskeletal Disorders, 18 (1). doi:10.1186/s12891-017-1585-2

Lazzarini, N., Runhaar, J., Bay-Jensen, A. C., Thudium, C. S., Bierma-Zeinstra, S. M. A., Henrotin, Y., & Bacardit, J. (2017). A machine learning approach for the identification of new biomarkers for knee osteoarthritis development in overweight and obese women. Osteoarthritis and Cartilage, 25 (12), 2014-2021. doi:10.1016/j.joca.2017.09.001

Legrand, C., Lambert, C., Comblain, F., Sanchez, C., & Henrotin, Y. (2017). Review of soluble biomarkers of osteoarthritis: lessons from animal model. Cartilage, 1-23. doi:10.1177/1947603516656739

Luo, Y., Sinkeviciute, D., He, Y., Karsdal, M., Henrotin, Y., Mobasheri, A., Önnerfjord, P., & Bay-Jensen, A. (2017). The minor collagens in articular cartilage. Protein and Cell, 8 (8), 560-572. doi:10.1007/s13238-017-0377-7

Mobasheri, A., Bay-Jensen, A.-C., Gualillo, O., Larkin, J., Levesque, M. C., & Henrotin, Y. (2017). Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice? Best Practice and Research. Clinical Rheumatology, 31, 705-720. doi:10.1016/j.berh.2018.07.002

Comblain, F., Dubuc, J.-E., Lambert, C., Sanchez, C., Lesponne, I., Serisier, S., & Henrotin, Y. (2016). Identification of Targets of a New Nutritional Mixture for Osteoarthritis Management Composed by Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract. PLoS ONE. doi:10.1371/journal.pone.0156902

Henrotin, Y., Sanchez, C., Bay-Jensen, A. C., & Mobasheri, A. (June 2016). Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives. Annals of Physical and Rehabilitation Medicine, 59 (3), 145-148. doi:10.1016/j.rehab.2016.03.004

Runhaar, J.* , Sanchez, C.* , Taralla, S., Henrotin, Y., & Bierma-Zeinstra, S. M. A. (April 2016). Fibulin-3 fragments are prognostic biomarkers of osteoarthritis incidence in overweight and obese women. Osteoarthritis and Cartilage, 24 (4), 672-678. doi:10.1016/j.joca.2015.10.013

Bay-Jensen, A.-C., Henrotin, Y., Karsdal, M., & Mobasheri, A. (2016). The need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA). EBioMedicine. doi:10.1016/j.ebiom.2016.05.004

Bay-Jensen, A. C., Reker, D., Kjelgaard-Petersen, C. F., Mobasheri, A., Karsdal, M. A., Ladel, C., Henrotin, Y., & Thudium, C. S. (2016). Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthritis and Cartilage, 24 (1), 9-20. doi:10.1016/j.joca.2015.10.014

Comblain, F., Serisier, S., Barthelemy, N., Balligand, M., & Henrotin, Y. (2016). Review of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014. Journal of Veterinary Pharmacology and Therapeutics, 39, 1-15. doi:10.1111/jvp.12251

Demoulin, C., Roussel, N., Marty, M., Mathy, C., Genevay, S., Henrotin, Y., Tomasella, M., Mahieu, G., & Vanderthommen, M. (2016). Les croyances délétères des patients lombalgiques : revue narrative de la littérature. Revue Médicale de Liège, 71 (1), 40-46.

Demoulin, C., Vanderthommen, M., GROSDENT, S., & Henrotin, Y. (2016). Techniques de réhabilitation abdominale et spinale pour le patient lombalgique. EMC - Kinésithérapie - Médecine Physique - Réadaptation.

Hochberg, M. C., Martel-Pelletier, J., Monfort, J., Moller, I., Castillo, J. R., Arden, N., Berenbaum, F., Blanco, F. J., Conaghan, P. G., Domenech, G., Henrotin, Y., Pap, T., Richette, P., Sawitzke, A., du Souich, P., Pelletier, J. P., & Group, M. I. (2016). Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases, 75 (1), 37-44. doi:10.1136/annrheumdis-2014-206792

Moller, I., Gharbi, M., Martinez Serrano, H., Herrero Barbero, M., Verges Milano, J., & Henrotin, Y. (2016). Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients. BMC Musculoskeletal Disorders, 17 (1), 416. doi:10.1186/s12891-016-1268-4

Sahebkar, A., & Henrotin, Y. (2016). Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Medicine. doi:10.1093/pm/pnv024

Oprenyeszk, F., Sanchez, C., Dubuc, J.-E., Maquet, V., Henrist, C., Compère, P., & Henrotin, Y. (28 May 2015). Chitosan enriched three-dimensional matrix reduces inflammatory and catabolic mediators production by human chondrocytes. PLoS ONE, 10 (5). doi:10.1371/journal.pone.0128362

Réeff, J., Oprenyeszk, F., Franck, T., Goole, J., De Vriese, C., Serteyn, D., Henrotin, Y., & Amighi, K. (28 April 2015). Development and evaluation in vitro and in vivo of injectable hydrolipidic gels with sustained-release properties for the management of articular pathologies such as osteoarthritis. International Journal of Pharmaceutics, 490, 74-84. doi:10.1016/j.ijpharm.2015.04.064

Comblain, F., Sanchez, C., Lesponne, I., Balligand, M., Serisier, S., & Henrotin, Y. (2015). Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract Synergically Inhibit Inflammatory and Catabolic Mediator's Synthesis by Normal Bovine and Osteoarthritic Human Chondrocytes in Monolayer. PLoS ONE. doi:10.1371/journal.pone.0121654

Henrotin, Y., Raman, R., Richette, P., Bard, H., Jerosch, J., Conrozier, T., Chevalier, X., & Migliore, A. (2015). Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Seminars in Arthritis and Rheumatism, 45 (2), 140-9. doi:10.1016/j.semarthrit.2015.04.011

Henrotin, Y., Sanchez, C., Cornet, A., Van de Put, J., Douette, P., & Gharbi, M. (2015). Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine. Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 20 (8), 540-6. doi:10.3109/1354750X.2015.1123363

Horcajada, M.-N.* , Sanchez, C.* , Membrez Scalfo, Drion, P., Comblain, F., Taralla, S., Donneau, A.-F., Offord, E. A., & Henrotin, Y. (2015). Oleuropein or rutin consumption decreases the spontaneous development of osteoarthritis in the Hartley guinea pig. Osteoarthritis and Cartilage, 23 (1), 94-102. doi:10.1016/j.joca.2014.08.016

Jordan, J. M., & Henrotin, Y. (2015). Osteoarthritis research society international initiative on recommendations for conducting clinical trials in osteoarthritis: overview. Osteoarthritis and Cartilage, 23 (5), 671-3. doi:10.1016/j.joca.2015.03.016

Kloppenburg, M., Maheu, E., Kraus, V. B., Cicuttini, F., Doherty, M., Dreiser, R. L., Henrotin, Y., Jiang, G. L., Mandl, L., Martel-Pelletier, J., Nelson, A. E., Neogi, T., Pelletier, J. P., Punzi, L., Ramonda, R., Simon, L. S., Wang, S., & Group, O. H. C. T. R. W. (2015). OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hand osteoarthritis. Osteoarthritis and Cartilage, 23 (5), 772-86. doi:10.1016/j.joca.2015.03.007

Kraus, V. B., Blanco, F. J., Englund, M., Henrotin, Y., Lohmander, L. S., Losina, E., Onnerfjord, P., & Persiani, S. (2015). OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis and Cartilage, 23 (5), 686-97. doi:10.1016/j.joca.2015.03.002

Landsmeer, M. L., Runhaar, J., Henrotin, Y., Middelkoop van, M., Oei, E. H., Vroegindeweij, D., Reijman, M., van Osch, G. J., Koes, B. W., Bindels, P. J., & Bierma-Zeinstra, S. M. A. (2015). Association of urinary biomarker COLL2-1NO2 with incident clinical and radiographic knee OA in overweight and obese women. Osteoarthritis and Cartilage, 23 (8), 1398-404. doi:10.1016/j.joca.2015.04.011

Lane, N. E., Hochberg, M. C., Nevitt, M. C., Simon, L. S., Nelson, A. E., Doherty, M., Henrotin, Y., & Flechsenhar, K. (2015). OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis. Osteoarthritis and Cartilage, 23 (5), 761-71. doi:10.1016/j.joca.2015.03.006

Mathy, C., Cedraschi, C., Broonen, J.-P., Azzi, A., & Henrotin, Y. (2015). Volition and low back pain: When patients talk. Annals of Physical and Rehabilitation Medicine, 58 (6), 326-31. doi:10.1016/j.rehab.2015.10.005

McAlindon, T. E., Bannuru, R. R., Sullivan, M. C., Arden, N. K., Berenbaum, F., Bierma-Zeinstra, S. M. A., Hawker, G. A., Henrotin, Y., Hunter, D. J., Kawaguchi, H., Kwoh, K., Lohmander, S., Rannou, F., Roos, E. M., & Underwood, M. (2015). Corrigendum to '2014 OARSI Guidelines for the Non-Surgical Management of Knee Osteoarthritis' [Osteoarthritis and Cartilage 22(2014) 363-388]. Osteoarthritis and Cartilage, 23 (6), 1026-1034. doi:10.1016/j.joca.2015.02.014

McAlindon, T. E., Driban, J. B., Henrotin, Y., Hunter, D. J., Jiang, G. L., Skou, S. T., Wang, S., & Schnitzer, T. (2015). OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthritis and Cartilage, 23 (5), 747-60. doi:10.1016/j.joca.2015.03.005

Mobasheri, A., & Henrotin, Y. (2015). Biomarkers of (osteo)arthritis. Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 20 (8), 513-8. doi:10.3109/1354750X.2016.1140930

Richette, P., Chevalier, X., Ea, H. K., Eymard, F., Henrotin, Y., Ornetti, P., Sellam, J., Cucherat, M., & Marty, M. (2015). Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open, 1 (1), 000071. doi:10.1136/rmdopen-2015-000071

Sanchez, C., Horcajada, M.-N., Membrez Scalfo, F., Ameye, L., Offord, E., & Henrotin, Y. (2015). Carnosol Inhibits Pro-Inflammatory and Catabolic Mediators of Cartilage Breakdown in Human Osteoarthritic Chondrocytes and Mediates Cross-Talk between Subchondral Bone Osteoblasts and Chondrocytes. PLoS ONE, 10 (8), 0136118. doi:10.1371/journal.pone.0136118

Henrotin, Y., & Mathy, C. (November 2014). Au stade aigu: traiter efficacement pour éviter le passage à la chronicité. Concours Medical, 136, 693-695.

Henrotin, Y., Lambert, C., & Richette, P. (April 2014). Importance of synovitis in osteoarthritis: Evidence for the use of glycosaminoglycans against synovial inflammation. Seminars in Arthritis and Rheumatism, 43 (5), 579-87. doi:10.1016/j.semarthrit.2013.10.005

Pesesse, L., Sanchez, C., Walsh, D., Delcour, J.-P., Baudouin, C., Msika, P., & Henrotin, Y. (April 2014). Bone sialoprotein as a potential key factor implicated in the pathophysiology of osteoarthritis. Osteoarthritis and Cartilage, 22 (4), 547-56. doi:10.1016/j.joca.2014.01.010

McAlindon, T. E., & Henrotin, Y. (March 2014). OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage, 22 (3), 363-388. doi:10.1016/j.joca.2014.01.003

Henrotin, Y., Pesesse, L., & Lambert, C. (February 2014). Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 6 (1), 20-34. doi:10.1177/1759720X13514669

Henrotin, Y. (2014). L'inhibition des voies de signalisation est-elle une possibilité thérapeutique pour l'arthrose? Revue du Rhumatisme, 81, 275-277. doi:10.1016/j.rhum.2014.02.005

Henrotin, Y. (2014). Does signalling pathways inhibition hold therapeutic promise for osteoarthritis? Joint Bone Spine, 81, 281-283. doi:10.1016/j.jbspin.2014.03.002

Henrotin, Y. (2014). Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complementary and Alternative Medicine. doi:10.1186/1472-6882-14-159

Henrotin, Y., Marty, M., & Mobasheri, A. (2014). What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas, 78, 184-187. doi:10.1016/j.maturitas.2014.04.015

Lambert, C., Dubuc, J.-E., Montell, E., Verges, J., Munaut, C., Noël, A., & Henrotin, Y. (2014). Gene expression pattern of synovial cells from inflammatory and normal areas of osteoarthritis synovial membrane. Arthritis and Rheumatism, sous presse. doi:10.1002/art.38315

Dobson, F., & Henrotin, Y. (October 2013). OARSI recommended performance-based tests to assess clinical function in osteoathritis of hip and knee: author's reply. Osteoarthritis and Cartilage, 21 (10), 1625-1626.

Oprenyeszk, F., Chausson, M., Maquet, V., Dubuc, J.-E., & Henrotin, Y. (August 2013). Protective effect of a new biomaterial against the development of experimental osteoarthritis lesions in rabbit: a pilot study evaluating the intra-articular injection of alginate-chitosan beads dispersed in an hydrogel. Osteoarthritis and Cartilage, 21 (8), 1099-1107. doi:10.1016/j.joca.2013.04.017

Gharbi, M., Sanchez, C., Mazzucchelli, G., De Pauw, E., & Henrotin, Y. (2013). Identification of differential pattern of protein expression in canine osteoarthritis serum after anterior cruciate ligament transection: a proteomic analysis. Veterinary Journal, 197 (3), 848-53. doi:10.1016/j.tvjl.2013.05.037

Henrotin, Y. (2013). L’instabilité cervicogénique. Réflexions Rhumatologiques, 17 (162), 11-13.

Henrotin, Y., Chevalier, X., DEBERG, M., Balblanc, J. C., Richette, P., Mulleman, D., Maillet, B., Rannou, F., Piroth, C., Mathieu, P., & Conrozier, T. (2013). Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO(2) ) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. Journal of Orthopaedic Research, 31 (6), 901-7. doi:10.1002/jor.22297

Henrotin, Y., Labasse, A., Franck, T., Bosseloir, A., Bury, T., & DEBERG, M. (2013). Collagen catabolism through Coll2-1 and Coll2-1NO and myeloperoxidase activity in marathon runners. SpringerPlus, 2 (1), 92. doi:10.1186/2193-1801-2-92

Henrotin, Y., & Lambert, C. (2013). Chondroitin and glucosamine in the management of osteoarthritis: an update. Current Rheumatology Reports. doi:10.1007/s11926-013-0361-z

Pesesse, L., Sanchez, C., Delcour, J.-P., Bellahcene, A., Baudouin, C., Msika, P., & Henrotin, Y. (2013). Consequences of chondrocyte hypertrophy on osteoarthritic cartilage: potential effect on angiogenesis. Osteoarthritis and Cartilage, 21 (12), 1913-23. doi:10.1016/j.joca.2013.08.018

Henrotin, Y., Pesesse, L., & Sanchez, C. (December 2012). Subchondral bone and osteoarthritis: biological and cellular aspects. Osteoporosis International, 23 (Suppl 8), 847–S851. doi:10.1007/s00198-012-2162-z

Lambert, C., Mathy-Hartert, M., Dubuc, J., Montell, E., Vergés, J., Munaut, C., Noël, A., & Henrotin, Y. (March 2012). Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Research and Therapy, 14 (2), 58. doi:10.1186/ar3771

Demoulin, C., Marty, M., Genevay, S., Vanderthommen, M., Mahieu, G., & Henrotin, Y. (2012). Effectiveness of preventive back educational interventions for low back pain: a critical review of randomized controlled clinical trials. European Spine Journal, 21, 2520-2530. doi:10.1007/s00586-012-2445-2

Henrotin, Y. (2012). Osteoarthritis year 2011 in review: biochemical markers of osteoarthritis: an overview of research and initiatives. Osteoarthritis and Cartilage, 20 (3), 215-7. doi:10.1016/j.joca.2012.01.008

Henrotin, Y. (2012). Interpretation of metaanalyses: pitfalls should be more widely recognized. Journal of Rheumatology, 39 (6), 1107-9. doi:10.3899/jrheum.111420

Henrotin, Y., Gharbi, M., Mazzucchelli, G., Dubuc, J.-E., De Pauw, E., & DEBERG, M. (2012). Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis and Rheumatism, 64 (7), 2260-7. doi:10.1002/art.34392

Henrotin, Y., Hauzeur, J.-P., Bruel, P., & Appelboom, T. (2012). Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters. BMC Research Notes, 5 (1), 407. doi:10.1186/1756-0500-5-407

Henrotin, Y., Martel-Pelletier, J., Msika, P., Guillou, G. B., & DEBERG, M. (2012). Usefulness of specific OA biomarkers, Coll2-1 and Coll2-1NO(2), in the anterior cruciate ligament OA canine model. Osteoarthritis and Cartilage, 20 (7), 787-90. doi:10.1016/j.joca.2012.03.016

Henrotin, Y., & Mobasheri, A. (2012). Soluble Biomarkers in Osteoarthritis – Current Status and Future Prospects? European Musculoskeletal Review, 7 (4), 217-220.

Henrotin, Y., Mobasheri, A., & Marty, M. (2012). Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Research and Therapy, 14 (1), 201. doi:10.1186/ar3657

Henrotin, Y., Pesesse, L., & Sanchez, C. (2012). L’os sous chondral et l’angiogenèse : deux nouvelles cibles thérapeutiques de l’arthrose. Réflexions Rhumatologiques, 16, 19-21.

Mobasheri, A., Henrotin, Y., Biesalski, H.-K., & Shakibaei, M. (2012). Scientific Evidence and Rationale for the Development of Curcumin and Resveratrol as Nutraceutricals for Joint Health. International Journal of Molecular Sciences, 13, 4202-4232. doi:10.3390/ijms13044202

Punzi, L., Ramonda, R., DEBERG, M., Frallonardo, P., Campana, C., Musacchio, E., & Henrotin, Y. (2012). Coll2-1, Coll2-1NO2 and myeloperoxidase serum levels in erosive and non-erosive osteoarthritis of the hands. Osteoarthritis and Cartilage, 20 (6), 557-61. doi:10.1016/j.joca.2012.02.638

Sanchez, C., Pesesse, L., Gabay, O., Delcour, J.-P., Msika, P., Baudouin, C., & Henrotin, Y. (2012). Regulation of subchondral bone osteoblast metabolism by cyclic compression. Arthritis and Rheumatism, 64 (4), 1193-203. doi:10.1002/art.33445

Broonen, J.-P., Marty, M., Legout, V., Cedraschi, C., & Henrotin, Y. (2011). La volition est-elle un chaînon manquant de la prise en charge du patient lombalgique ? Revue du Rhumatisme, 78 (1), 238-41. doi:10.1016/j.rhum.2010.08.019

Broonen, J.-P., Marty, M., Legout, V., Cedraschi, C., & Henrotin, Y. (2011). Is volition the missing link in the management of low back pain? Joint Bone Spine, 78, 364-367. doi:10.1016/j.jbspin.2010.10.009

Conrozier, T., Balblanc, J. C., Richette, P., Mulleman, D., Maillet, B., Henrotin, Y., Rannou, F., Piroth, C., Hilliquin, P., Mathieu, P., Walliser-Lohse, A., Rousselot, I., Plattner, V., Maillefert, J. F., Vignon, E., & Chevalier, X. (2011). Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study. Journal of Orthopaedic Research. doi:10.1002/jor.21580

Gharbi, M., Deberg, M., & Henrotin, Y. (2011). Application for proteomic techniques in studying osteoarthritis: a review. Frontiers in Physiology, 2 (90), 4-14. doi:10.3389/fphys.2011.00090

Henrotin, Y. (2011). Muscle: a source of progenitor cells for bone fracture healing. BMC Medicine, 9, 136. doi:10.1186/1741-7015-9-136

Henrotin, Y., Lambert, C., Couchourel, D., Ripoll, C., & Chiotelli, E. (2011). Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. Osteoarthritis and Cartilage, 19 (1), 1-21. doi:10.1016/j.joca.2010.10.017

Henrotin, Y., Moyse, D., Bazin, T., Cedraschi, C., Duplan, B., Duquesnoy, B., Laroche, F., Valat, J.-P., & Marty, M. (2011). Study of the information delivery by general practitioners and rheumatologists to patients with acute low back pain. European Spine Journal, 20 (5), 720-30. doi:10.1007/s00586-010-1612-6

Henrotin, Y., Pesesse, L., & Sanchez, C. (2011). La dégénérescence discale est-elle une histoire d’« Os » ? Revue du Rhumatisme, 78, 3-7. doi:10.1016/j.monrhu.2010.09.004

Kraus, V. B., Burnett, B., Coindreau, J., Cottrell, S., Eyre, D., Gendreau, M., Gardiner, J., Garnero, P., Hardin, J., Henrotin, Y., Heinegard, D., Ko, A., Lohmander, L. S., Matthews, G., Menetski, J., Moskowitz, R., Persiani, S., Poole, A. R., Rousseau, J.-C., & Todman, M. (2011). Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis and Cartilage, 19 (5), 515-42. doi:10.1016/j.joca.2010.08.019

Mathy, C., Broonen, J.-P., Henrotin, Y., Marty, M., Legout, V., Genevay, S., Duplan, B., Bazin, T., Laroche, F., Savarieau, B., & Cedraschi, C. (2011). Development and validation of a questionnaire assessing volitional competencies to enhance the performance of physical activities in chronic low back pain patients. BMC Musculoskeletal Disorders, 12, 111. doi:10.1186/1471-2474-12-111

Mobasheri, A., & Henrotin, Y. (2011). Biomarkers of Osteoarthritis: A Review of Recent Research Progress on Soluble Biochemical Markers, Published Patents and Areas for Future Development. Recent Patents on Biomarkers, 1 (1), 25-43.

Perrot, S., Marty, M., Legout, V., Moyse, D., Henrotin, Y., & Rozenberg, S. (2011). Ecological or recalled assessments in chronic musculoskeletal pain? A comparative study of prospective and recalled pain assessments in low back pain and lower limb painful osteoarthritis. Pain Medicine, 12 (3), 427-36. doi:10.1111/j.1526-4637.2011.01052.x

Pesesse, L., Sanchez, C., & Henrotin, Y. (2011). Osteochondral plate angiogenesis: A new treatment target in osteoarthritis. Joint Bone Spine, 78, 144-149. doi:10.1016/j.jbspin.2010.07.001

Pesesse, L., Sanchez, C., & Henrotin, Y. (2011). Néovascularisation de la plaque ostéochondrale : nouvelle cible thérapeutique del'arthrose. Revue du Rhumatisme, 78 (1), 12-17. doi:10.1016/j.rhum.2010.05.004

Rego-Perez, I., Fernandez-Moreno, M., Deberg, M., Pertega, S., Fernandez-Lopez, C., Oreiro, N., Henrotin, Y., & Blanco, F. J. (2011). Mitochondrial DNA haplogroups and serum levels of proteolytic enzymes in patients with osteoarthritis. Annals of the Rheumatic Diseases, 70 (4), 646-52. doi:10.1136/ard.2010.133637

Verwilghen, D., Enzerink, E., Martens, A., Franck, T., Balligand, M., Henrotin, Y., Detilleux, J., & Serteyn, D. (2011). Relationship between arthroscopic joint evaluation and the levels of Coll2-1, Coll2-1NO(2), and myeloperoxidase in the blood and synovial fluid of horses affected with osteochondrosis of the tarsocrural joint. Osteoarthritis and Cartilage, 19 (11), 1323-9. doi:10.1016/j.joca.2011.08.002

Verwilghen, D., Martens, A., Busschers, E., Franck, T., Deberg, M., Henrotin, Y., Vander Heyden, L., & Serteyn, D. (2011). Coll2-1, Coll2-1NO2 and myeloperoxidase concentrations in the synovial fluid of equine tarsocrural joints affected with osteochondrosis. Veterinary Research Communications, 35 (7), 401-8. doi:10.1007/s11259-011-9487-5

Henrotin, Y. (2010). Recommandations européennes pour la prise en charge des patients souffrant de lombalgie aiguë et chronique. Kinesitherapie, La Revue, 108, 14-15. doi:10.1016/S1779-0123(10)74974-3

Henrotin, Y., & Chevalier, X. (2010). Recommandations sur la prise en charge de l'arthrose de la hanche et du genou: pour qui ? Pourquoi ? Pourquoi faire ? Presse Médicale, 39 (11), 1180-1188.

Henrotin, Y., & Chevalier, X. (2010). Recommandations sur la prise en charge de l'arthrose de la hanche et du genou. Pour qui ? Pourquoi ? Pour quoi faire ? Presse Médicale. doi:10.1016/j.lpm.2010.03.029

Henrotin, Y., Clutterbuck, A. L., Allaway, D., Lodwig, E. M., Harris, P., Mathy, M., Shakibaei, M., & Mobasheri, A. (2010). Biological actions of curcumin on articular chondrocytes. Osteoarthritis and Cartilage, 18 (2), 141-9. doi:10.1016/j.joca.2009.10.002

Henrotin, Y., & DEBERG, M. (2010). Les marqueurs biologiques du collagène de type II. De nouveaux outils d'évaluation de l'arthrose. Ortho-Rhumato, 8 (6), 226-230.

Henrotin, Y., & Deberg, M. (2010). De nouveaux outils d’évaluation de l’arthrose. Ortho-Rhumato, 8, 1-5.

Henrotin, Y., Mathy, M., Sanchez, C., & Lambert, C. (2010). Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Therapeutic Advances in Musculoskeletal Disease, 2 (6), 335-348. doi:10.1177/1759720X10383076

Henrotin, Y., & Mobasheri, A. (2010). Curcumin in the treatment of osteoarthritis: the proof-of-concept. Journal of Tropical Medicinal Plants, 10 (2), 123-132.

Herman, L., Hubert, P., Herfs, M., Kustermans, G., Henrotin, Y., Bousarghin, L., Boniver, J., & Delvenne, P. (2010). The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context. European Journal of Immunology, 40 (11), 3075-84. doi:10.1002/eji.201040571

Huebner, J. L., Williams, J. M., Deberg, M., Henrotin, Y., & Kraus, V. B. (2010). Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis and Cartilage, 18 (3), 397-405. doi:10.1016/j.joca.2009.09.011

Mobasheri, A., & Henrotin, Y. (2010). Identification, validation and qualification of biomarkers for osteoarthritis in humans and companion animals: mission for the next decade. Veterinary Journal, 185 (2), 95-7. doi:10.1016/j.tvjl.2010.05.026

Rego-Perez, I., Fernandez-Moreno, M., Deberg, M., Pertega, S., Fenandez-Lopez, C., Oreiro, N., Henrotin, Y., & Blanco, F. J. (2010). Mitochondrial DNA haplogroups modulate the serum levels of biomarkers in patients with osteoarthritis. Annals of the Rheumatic Diseases, 69 (5), 910-7. doi:10.1136/ard.2009.117416

Richette, P., Eymard, C., Deberg, M., Vidaud, D., de Kerguenec, C., Valla, D., Vicaut, E., Bardin, T., & Henrotin, Y. (2010). Increase in type II collagen turnover after iron depletion in patients with hereditary haemochromatosis. Rheumatology, 49 (4), 760-6. doi:10.1093/rheumatology/kep429

Mathy, M., Jacquemond-Collet, I., Priem, F., Sanchez, C., Lambert, C., & Henrotin, Y. (December 2009). Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflammation Research, 58, 899-908. doi:10.1007/s00011-009-0063-1

Herfs, M., Herman, L., Hubert, P., Minner, F., Arafa, M. M. M., Roncarati, P., Henrotin, Y., Boniver, J., & Delvenne, P. (April 2009). High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunology, Immunotherapy, 58 (4), 603-614. doi:10.1007/s00262-008-0584-4

Chevalier, X., & Henrotin, Y. (2009). OARSI recommendations on knee and hip osteoarthritis: use with discernment. Joint Bone Spine, 76 (5), 455-7. doi:10.1016/j.jbspin.2009.04.005

Henrotin, Y. (2009). Need for high-standard translation methodology for the dissemination of guidelines. Osteoarthritis and Cartilage, 17 (12), 1536-8. doi:10.1016/j.joca.2009.06.005

Henrotin, Y., Deberg, M., Mathy, M., & Deby-Dupont, G. (2009). Biochemical biomarkers of oxidative collagen damage. Advances in Clinical Chemistry, 49, 31-55. doi:10.1016/S0065-2423(09)49002-4

Henrotin, Y., & Dubuc, J.-E. (2009). Cartilage repair in osteoarthritic patients: utopia or real opportunity? F1000 Reports Medecine, 1, 88. doi:10.3410/M1-88

Henrotin, Y., Marty, M., Appelboom, T., Avouac, B., Berenbaum, F., Briole, V., Djian, P., Dougados, M., Forestier, R., Genevay, S., Lequesne, M., Maheu, E., Poiraudeau, S., Rannou, F., Richette, P., Spector, T., Dubuc, J.-E., & Chevalier, X. (2009). Traduction française des recommandations de l’Osteoarthritis Research Society International (OARSI) sur la prise en charge de la gonarthrose et de la coxarthrose. Revue du Rhumatisme, 76, 279-288. doi:10.1016/j.rhum.2008.07.020

Henrotin, Y., Pesesse, L., & Sanchez, C. (2009). Subchondral bone in osteoarthritis physiopathology: state-of-the art and perspectives. Bio-medical Materials and Engineering, 19 (4-5), 311-6. doi:10.3233/BME-2009-0596

Marty, M., & Henrotin, Y. (2009). Information for patients with low back pain: from research to clinical practice. Joint Bone Spine, 76 (6), 621-2. doi:10.1016/j.jbspin.2009.09.003

Marty, M., Rozenberg, S., Legout, V., Durand-Zaleski, I., Moyse, D., Henrotin, Y., & Perrot, S. (2009). Influence of time, activities, and memory on the assessment of chronic low back pain intensity. Spine, 34 (15), 1604-9. doi:10.1097/BRS.0b013e3181a15359

Sanchez, C., Gabay, O., Salvat, C., Henrotin, Y., & Berenbaum, F. (2009). Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis and Cartilage, 17 (4), 473-81. doi:10.1016/j.joca.2008.09.007

Verwilghen, D., Busoni, V., Gangl, M., Franck, T., Lejeune, J.-P., Vander Heyden, L., Detilleux, J., Grulke, S., Deberg, M., Henrotin, Y., & Serteyn, D. (2009). Relationship between biochemical markers and radiographic scores in the evaluation of the osteoarticular status of Warmblood stallions. Research in Veterinary Science, 87 (2), 319-28. doi:10.1016/j.rvsc.2009.02.002

Gabay, O., Hall, D., Berenbaum, F., Henrotin, Y., & Sanchez, C. (December 2008). Arthrose et obésité : Modèles expérimentaux. Revue du Rhumatisme, 75 (12), 1215-1219. doi:10.1016/j.rhum.2008.07.015

Henrotin, Y. (2008). Avocado/Soybean Unsaponifiable (Asu) to Treat Osteoarthritis: A Clarification. Osteoarthritis and Cartilage. doi:10.1016/j.joca.2008.01.010

Mathy, M., Hogge, L., Sanchez, C., Deby, G., Crielaard, J.-M., & Henrotin, Y. (10 February 2008). Interleukin-1beta and Interleukin-6 Disturb the Antioxidant Enzyme System in Bovine Chondrocytes: A Possible Explanation for Oxidative Stress Generation. Osteoarthritis and Cartilage, 16, 756-763. doi:10.1016/j.joca.2007.10.009

Deberg, M., Dubuc, J. E., Labasse, A., Sanchez, C., Quettier, E., Bosseloir, A., Crielaard, J.-M., & Henrotin, Y. (February 2008). One-Year Follow-up of Coll2-1, Coll2-1no2 and Myeloperoxydase Serum Levels in Osteoarthritis Patients after Hip or Knee Replacement. Annals of the Rheumatic Diseases, 67 (2), 168-74. doi:10.1136/ard.2007.073452

Sanchez, C., Deberg, M., Bellahcene, A., Castronovo, V., Msika, P., Delcour, J.-P., Crielaard, J.-M., & Henrotin, Y. (February 2008). Phenotypic Characterization of Osteoblasts from the Sclerotic Zones of Osteoarthritic Subchondral Bone. Arthritis and Rheumatism, 58 (2), 442-55. doi:10.1002/art.23159

Gabay, O., Hall, D., Berenbaum, F., Henrotin, Y., & Sanchez, C. (2008). Osteoarthritis and obesity: Experimental models. Joint Bone Spine, 75, 675-679. doi:10.1016/j.jbspin.2008.07.011

Sanchez, C., Gabay, O., Henrotin, Y., & Berenbaum, F. (2008). Osteoblast: A cell under compression. Bio-medical Materials and Engineering, 18 (4-5), 221-4. doi:10.3233/BME-2008-0528

Lamour, V., Detry, C., Sanchez, C., Henrotin, Y., Castronovo, V., & Bellahcene, A. (14 December 2007). Runx2-and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. Journal of Biological Chemistry, 282 (50), 36240-36249. doi:10.1074/jbc.M705833200

Ameye, L. G., Deberg, M., Oliveira, M., Labasse, A., Aeschlimann, J. M., & Henrotin, Y. (October 2007). The chemical biomarkers C2C, Coll2-1, and Coll2-1NO(2) provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis and Rheumatism, 56 (10), 3336-3346. doi:10.1002/art.22875

Lejeune, J.-P., Serteyn, D., Gangl, M., Schneider, N., Deby-Dupont, G., Deberg, M., & Henrotin, Y. (July 2007). Plasma concentrations of a type II collagen-derived peptide and its nitrated form in growing ardenner sound horses and in horses suffering from juvenile digital degenerative osteoarthropathy. Veterinary Research Communications, 31 (5), 591-601. doi:10.1007/s11259-007-3518-2

Gangl, M., Deberg, M., Lejeune, J.-P., Schneider, N., Grulke, S., Peters, F., Vila, T., Deby-Dupont, G., Serteyn, D., & Henrotin, Y. (2007). A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions. Research in Veterinary Science, 82, 68-75. doi:10.1016/j.rvsc.2006.03.008

Henrotin, Y., Addison, S., Kraus, V., & Deberg, M. (2007). Type II collagen markers in osteoarthritis: what do they indicate? Current Opinion in Rheumatology, 19 (5), 444-50. doi:10.1097/BOR.0b013e32829fb3b5

Henrotin, Y., Blanco, F., Aigner, T., & Kurz, B. (2007). The Significance of Oxidative Stress in Articular Cartilage Ageing and Degradation. Current Rheumatology Reviews, 3, 261-274. doi:10.2174/157339707782408955

Henrotin, Y., & Kurz, B. (2007). Antioxidant to treat osteoarthritis: dream or reality? Current Drug Targets, 8 (2), 347-57. doi:10.2174/138945007779940151

Henrotin, Y., Deberg, M., Crielaard, J.-M., Piccardi, N., Msika, P., & Sanchez, C. (August 2006). Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. Journal of Rheumatology, 33 (8), 1668-1678.

Burton, A. K., Balague, F., Cardon, G., Eriksen, H. R., Henrotin, Y., Lahad, A., Leclerc, A., Muller, G., & van der Beek, A. J. (2006). Chapter 2. European guidelines for prevention in low back pain : November 2004. European Spine Journal, 15 Suppl 2, 136-68. doi:10.1007/s00586-006-1070-3

Henrotin, Y. (2006). Nutraceuticals in the management of osteoarthritis: an overview. Journal of Veterinary Pharmacology and Therapeutics, 29 (Suppl. 1), 201-203.

Henrotin, Y., Rozenberg, S., Balagué, F., Leclerc, A., Roux, E., Cédraschi, C., Marty, M., & Valat, J.-P. (2006). Recommandations européennes (COST B13) en matière de prévention et pour la prise en charge de la lombalgie non spécifique. Revue du Rhumatisme, 73 (Suppl 2), 35-52.

Lejeune, J.-P., Schneider, N., Henrotin, Y., & Serteyn, D. (2006). Degenerative osteoarthropathy in horses: pathogeny and diagnostic. Annales de Médecine Vétérinaire, 150 (3), 173-192.

Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (November 2005). Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 13 (11), 988-997. doi:10.1016/j.joca.2005.07.012

Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (November 2005). Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1 beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis and Cartilage, 13 (11), 979-987. doi:10.1016/j.joca.2005.03.008

Henrotin, Y., Sanchez, C., & Balligand, M. (July 2005). Pharmaceutical and nutraceutical management of canine osteoarthritis: Present and future perspectives. Veterinary Journal, 170 (1), 113-123. doi:10.1016/j.tvjl.2004.08.014

Jupsin, I., Collette, J., Henrotin, Y., Bruyère, O., Sarlet, N., & Reginster, J.-Y. (April 2005). Strontium Ranelate (Fujisawa/Servier). Current Opinion in Investigational Drugs, 6 (4), 435-44.

Deberg, M., Labasse, A., Christgau, S., Cloos, P., Bang Henriksen, D., Chapelle, J.-P., Zegels, B., Reginster, J.-Y., & Henrotin, Y. (March 2005). New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage, 13 (3), 258-265. doi:10.1016/j.joca.2004.12.002

Deberg, M., Labasse, A., Collette, J., Seidel, L., Reginster, J.-Y., & Henrotin, Y. (2005). One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis and Cartilage, 13 (12), 1059-65. doi:10.1016/j.joca.2005.06.014

Demoulin, C., Fauconnier, C., Vanderthommen, M., & Henrotin, Y. (2005). Recommandations pour l'elaboration d'un bilan fonctionnel de base du patient lombalgique. Revue Médicale de Liège, 60 (7-8, Jul-Aug), 661-8.

Henrotin, Y., Kurz, B., & Aigner, T. (2005). Oxygen and reactive oxygen species in cartilage degradation: friends or foes? Osteoarthritis and Cartilage, 13 (8), 643-54. doi:10.1016/j.joca.2005.04.002

Martin, G., Andriamanalijaona, R., Mathy, M., Henrotin, Y., & Pujol, J.-P. (2005). Comparative effects of IL-1beta and hydrogen peroxide (H2O2) on catabolic and anabolic gene expression in juvenile bovine chondrocytes. Osteoarthritis and Cartilage, 13 (10), 915-24. doi:10.1016/j.joca.2005.03.009

Mathy, M., Burton, S., Deby, G., Devel, P., Reginster, J.-Y., & Henrotin, Y. (2005). Influence of oxygen tension on nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes. Osteoarthritis and Cartilage, 13 (1), 74-9. doi:10.1016/j.joca.2004.09.009

Muller, G., Burton, A., Balague, F., Cardon, G., Eriksen, H., Henrotin, Y., Lahad, A., Leclerc, A., & Vanderbeek, A. (2005). Evidence for the efficacy of preventive means for low back pain. Physioscience, 1, 100-12.

Reginster, J.-Y., Bruyère, O., Fraikin, G., & Henrotin, Y. (2005). Current Concepts in the Therapeutic Management of Osteoarthritis with Glucosamine. Bulletin. Hospital for Joint Diseases, 63 (1-2), 31-36.

Sanchez, C., Deberg, M., Devel, P., Reginster, J.-Y., Henrotin, Y., & Burton, S. (October 2004). Differential Regulation of Chondrocyte Metabolism by Oncostatin M and Interleukin-6. Osteoarthritis and Cartilage, 12 (10), 801-10. doi:10.1016/j.joca.2004.06.011

Reginster, J.-Y., Sarkar, S., Zegels, B., Henrotin, Y., Bruyère, O., Agnusdei, D., & Collette, J. (February 2004). Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. BONE, 34 (2), 344-351. doi:10.1016/j.bone.2003.10.004

Christgau, S., Henrotin, Y., Tanko, L. B., Rovati, L. C., Collette, J., Bruyère, O., Deroisy, R., & Reginster, J.-Y. (2004). Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clinical and Experimental Rheumatology, 22 (1, JAN-FEB), 36-42.

Henrotin, Y., Deberg, M., Dubuc, J. E., Quettier, E., Christgau, S., & Reginster, J.-Y. (2004). Type II collagen peptides for measuring cartilage degradation. Biorheology, 41 (3-4), 543-547.

Martin, G., Andriamanalijaona, R., Grassel, S., Dreier, R., Mathy, M., Bogdanowicz, P., Boumediene, K., Henrotin, Y., Bruckner, P., & Pujol, J.-P. (2004). Effect of hypoxia and reoxygenation on gene expression and response to interleukin-1 in cultured articular chondrocytes. Arthritis and Rheumatism, 50 (11), 3549-60. doi:10.1002/art.20596

Mouithys-Mickalad, A., Deby, G., Mathy, M., Habraken, Y., Nys, M., Henrotin, Y., Lamy, M., & Deby, C. (2004). Effects of glucocorticoids on the respiratory burst of Chlamydia-primed THP-1 cells. Biochemical and Biophysical Research Communications, 318 (4), 941-8. doi:10.1016/j.bbrc.2004.04.120

Reginster, J.-Y., & Henrotin, Y. (2004). Les nouveaux médicaments de l'arthrose. Pharma-Sphère, 85, 22-25.

Reginster, J.-Y., Bruyère, O., Lecart, M.-P., & Henrotin, Y. (September 2003). Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. Current Opinion in Rheumatology, 15, 651-655. doi:10.1097/00002281-200309000-00022

Henrotin, Y., Sanchez, C., Deberg, M., Piccardi, N., Guillou, G. B., Msika, P., & Reginster, J.-Y. (August 2003). Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. Journal of Rheumatology, 30 (8), 1825-1834.

Reginster, J.-Y., Bruyère, O., & Henrotin, Y. (August 2003). New perspectives in the management of osteoarthritis. Structure modification: Facts or fantasy? Journal of Rheumatology. Supplement, 67 (Suppl. 67), 14-20.

Richy, F., Bruyère, O., Ethgen, O., Cucherat, M., Henrotin, Y., & Reginster, J.-Y. (14 July 2003). Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis - A comprehensive meta-analysis. Archives of Internal Medicine, 163 (13), 1514-1522. doi:10.1001/archinte.163.13.1514

Bruyère, O., COLLETTE, J., Ethgen, O., Rovati, L. C., Giacovelli, G., Henrotin, Y., Seidel, L., & Reginster, J.-Y. (May 2003). Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. Journal of Rheumatology, 30 (5), 1043-50.

Bruyère, O., Dardenne, C.-B., Lejeune, E., Zegels, B., Pahaut, A., Richy, F., Seidel, L., Ethgen, O., Henrotin, Y., & Reginster, J.-Y. (May 2003). Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. BONE, 32 (5), 541-545. doi:10.1016/S8756-3282(03)00059-0

Bruyère, O., Henrotin, Y., Honore, A., Rovati, L. C., Seidel, L., Dardenne, C.-B., & Reginster, J.-Y. (April 2003). Impact of the joint space width measurement method on the design of knee osteoarthritis studies. Aging Clinical and Experimental Research, 15 (2), 136-41. doi:10.1007/BF03324491

Reginster, J.-Y., Kvasz, A., Bruyère, O., & Henrotin, Y. (February 2003). is there any rationale for prescribing hormone replacement therapy (HTR) to prevent or to treat osteoarthritis? Osteoarthritis and Cartilage, 11 (2), 87-91. doi:10.1053/joca.2002.0872

Sanchez, C., Mathy-Hartert, M., Deberg, M., Ficheux, H., Reginster, J.-Y., & Henrotin, Y. (01 February 2003). Effects of rhein on human articular chondrocytes in alginate beads. Biochemical Pharmacology, 65 (3), 377-388. doi:10.1016/S0006-2952(02)01485-5

Bruyère, O., Honore, A., Ethgen, O., Rovati, L. C., Giacovelli, G., Henrotin, Y., Seidel, L., & Reginster, J.-Y. (January 2003). Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis and Cartilage, 11 (1), 1-5. doi:10.1053/joca.2002.0848

Henrotin, Y., Bruckner, P., & Pujol, J. P. (2003). The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis and Cartilage, 11 (10), 747-55. doi:10.1016/S1063-4584(03)00150-X

Mathy, M., Martin, G., Devel, P., Deby, G., Pujol, J. P., Reginster, J.-Y., & Henrotin, Y. (2003). Reactive oxygen species downregulate the expression of pro-inflammatory genes by human chondrocytes. Inflammation Research, 52 (3), 111-8. doi:10.1007/s000110300023

Mayer, F., Schlumberger, A., van Cingel, R., Henrotin, Y., Laube, W., & Schmidtbleicher, D. (2003). Training and testing in open versus closed kinetic chain. Isokinetics and Exercise Science, 11, 181-7. doi:10.3233/ies-2003-0154

Sanchez, C., Mateus, M., Defresne, M.-P., Crielaard, J.-M., Reginster, J.-Y., & Henrotin, Y. (April 2002). Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1 beta and nonsteroidal antiinflammatory drugs. Journal of Rheumatology, 29 (4), 772-782.

Ayache, N., Boumediene, K., Mathy, M., Reginster, J.-Y., Henrotin, Y., & Pujol, J.-P. (2002). Expression of TGF-betas and their receptors is differentially modulated by reactive oxygen species and nitric oxide in human articular chondrocytes. Osteoarthritis and Cartilage, 10 (5), 344-52. doi:10.1053/joca.2001.0499

Bruyère, O., Honore, A., Rovati, L. C., Giacovelli, G., Henrotin, Y., Seidel, L., & Reginster, J.-Y. (2002). Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scandinavian Journal of Rheumatology, 31 (1), 13-6. doi:10.1080/030097402317255309

Henrotin, Y., Sanchez, C., & Reginster, J.-Y. (January 2002). The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opinion on Therapeutic Patents, 12 (1), 29-43. doi:10.1517/13543776.12.1.29

Mathy, M., Deby, G., Reginster, J.-Y., Ayache, N., Pujol, J.-P., & Henrotin, Y. (2002). Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes. Osteoarthritis and Cartilage, 10 (7), 547-55. doi:10.1053/joca.2002.0789

Van Tulder, M., Kovacs, F., Müller, G., Airaksinen, O., Balagué, F., Broos, L., Burton, K., Gil del Real, M.-T., Hänninnen, O., & Henrotin, Y. (2002). European guidelines for the management of low back pain. Acta Orthopaedica Scandinavica. Supplement, 73 ((Suppl 305)), 20-25.

Reginster, J.-Y., Paul, I., & Henrotin, Y. (July 2001). Comment positionner l'acéclofénac au sein de l'arsenal thérapeutique des pathologies ostéo-articulaires chroniques ? Revue Médicale de Liège, 56 (7), 484-8.

Henrotin, Y., Deby-Dupont, G., & Reginster, J.-Y. (June 2001). Les mediateurs biochimiques de l'inflammation. Revue Médicale de Liège, 56 (6), 433-42.

Reginster, J.-Y., & Henrotin, Y. (March 2001). Pharma clinics. Comment je traite.... L'arthrose. 2eme partie: Nouvelles perspectives therapeutiques. Revue Médicale de Liège, 56 (3), 135-9.

Reginster, J.-Y., & Henrotin, Y. (February 2001). Pharma clinics. Comment je traite.... L'arthrose. 1ère partie: Rappel physiopathologique et traitement symptomatique. Revue Médicale de Liège, 56 (2), 63-7.

Appelboom, T., Schuermans, J., Verbruggen, G., Henrotin, Y., & REGINSTER, J.-Y. (2001). Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scandinavian Journal of Rheumatology, 30 (4), 242-7. doi:10.1080/030097401316909602

Crielaard, J.-M., Henrotin, Y., DEFAWEUX, M., TOMASELLA, M., & Vanderthommen, M. (2001). L'Ecole du dos. Bulletin d'Éducation du Patient à sa Maladie, 20, 21-22.

De Leval, X., Delarge, J., Devel, P., Neven, P., Michaux, C., Masereel, B., Pirotte, B., David, J. L., Henrotin, Y., & Dogne, J.-M. (2001). Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 64, 211-216. doi:10.1054/plef.2001.0262

Henrotin, Y., de Leval, X., Mathy, M., Mouithys-Mickalad, A., Deby, G., Dogné, J.-M., Delarge, J., & Reginster, J.-Y. (2001). In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflammation Research, 50 (8), 391-9. doi:10.1007/PL00000261

Henrotin, Y., Labasse, A., Zheng, S. X., Galais, P., Tsouderos, Y., Crielaard, J.-M., & Reginster, J.-Y. (2001). Strontium ranelate increases cartilage matrix formation. Journal of Bone and Mineral Research, 16 (2), 299-308. doi:10.1359/jbmr.2001.16.2.299

Henrotin, Y., Vanderthommen, M., Fauconnier, C., Grisart, J., Masquelier, E., Peretz, A., Toussaint, F., Lemaitre, D., Angenot, P., Mahieu, G., Rossion, P., Bailly, D., Mahy, J. L., Chif, D., Dechef, P., & Crielaard, J.-M. (2001). Définition, critères de qualité et évaluation d'un programme de type école du dos. Recommandations de la Société belge des écoles du dos. Revue du Rhumatisme, 68, 185-191. doi:10.1016/S1169-8330(00)00095-8

Reginster, J.-Y., Deroisy, R., Rovati, L. C., Lee, R. L., Lejeune, E., Bruyère, O., Giacovelli, G., Henrotin, Y., Dacre, J. E., & Gosset, C. (January 2001). Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. The Lancet, 357, 251-256. doi:10.1016/S0140-6736(00)03610-2

Reginster, J.-Y., Henrotin, Y., Christiansen, C., Gamwell-Henriksen, E., Bruyère, O., Collette, J., & Christgau, S. (2001). Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcified Tissue International, 69 (3), 130-137. doi:10.1007/s002230020042

Zheng, S. X., Mouithys-Mickalad, A., Dupont, G., Deby, C., Maroulis, A. P., Labasse, A. H., Lamy, M., Crielaard, J.-M., Reginster, J.-Y., & Henrotin, Y. (November 2000). In Vitro Study of the Antioxidant Properties of Nimesulide and 4-Oh Nimesulide: Effects on Hrp- and Luminol-Dependent Chemiluminescence Produced by Human Chondrocytes. Osteoarthritis and Cartilage, 8 (6), 419-25. doi:10.1053/joca.1999.0317

De Leval, X., Delarge, J., Somers, F., De Tullio, P., Henrotin, Y., Pirotte, B., & Dogne, J.-M. (2000). Recent advances in inducible cyclooxygenase (COX-2) inhibition. Current Medicinal Chemistry, 7 (10), 1041-1062. doi:10.2174/0929867003374417

De Leval, X., Henrotin, Y., Labasse, A., Reginster, J.-Y., Neven, P., Delarge, J., Somers, F., Masereel, B., Pirotte, B., & Dogne, J.-M. (2000). Comparison of the effects of nimesulide and nimesulide-L-lysine on PGE2 production by COX-1 and COX-2 and on chondrocyte metabolism in vitro. Pharmacy and Pharmacology Communications, 6, 83-87. doi:10.1211/146080800128735683

Henrotin, Y., Croisier, J.-L., Reginster, J.-Y., & CRIELAARD, J.-M. (2000). Bases scientifiques du traitement physique de la gonarthrose. Kiné 2000 : Revue Européenne de la Kinésitherapie, 11 (4), 86-94.

Henrotin, Y., Zheng, S. X., Labasse, A. H., Dupont, G., Crielaard, J.-M., & REGINSTER, J.-Y. (2000). Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis and Cartilage, 8 (6), 474-82. doi:10.1053/joca.1999.0323

Mouithys-Mickalad, A., Zheng, S. X., Dupont, G., Deby, C., Lamy, M., Reginster, J.-Y., & Henrotin, Y. (2000). In vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Free Radical Research, 33 (5), 607-21. doi:10.1080/10715760000301131

Reginster, J.-Y., Gillot, V., Bruyère, O., & Henrotin, Y. (2000). Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Current Rheumatology Reports, 2 (6), 472-477. doi:10.1007/s11926-000-0023-9

Reginster, J.-Y., & Henrotin, Y. (2000). Conception actuelle du traitement de l’arthrose. Revue de la Médecine Générale, 177, 382-389.

Henrotin, Y., & Reginster, J.-Y. (May 1999). In-Vitro Differences among Nonsteroidal Antiinflammatory Drugs in Their Activities Related to Osteoarthritis Pathophysiology. Osteoarthritis and Cartilage, 7 (3), 355-7. doi:10.1053/joca.1998.0197

Henrotin, Y., & Reginster, J.-Y. (May 1999). Anabolic Events in Osteoarthritis. Osteoarthritis and Cartilage, 7 (3), 310-2. doi:10.1053/joca.1998.0175

Reginster, J.-Y., Henrotin, Y., & Gosset, C. (March 1999). Promising New Agents in Osteoporosis. Drugs in R&D, 1 (3), 195-201. doi:10.2165/00126839-199901030-00001

de Leval, X., Dogné, J.-M., Neven, P., Labasse, A., Delarge, J., Reginster, J.-Y., & Henrotin, Y. (1999). Effects of Nimesulide and Indometacin on Cox-1 and Cox-2: A Comparative Study. Journal de Pharmacie de Belgique, 54 (3), 89-90.

Henrotin, Y., Labasse, A., Guillou, B., Crielaard, J.-M., & Reginster, J.-Y. (1999). Advocado/soybean unsaponifiable mixture increased high molecular weight proteoglycans synthesis by human articular chondrocytes. Annals of Rheumatoid Arthritis, 230, 963.

Henrotin, Y., Labasse, A. H., Simonis, P. E., Zheng, S. X., Dupont, G., Famaey, J. P., Crielaard, J.-M., & Reginster, J.-Y. (1999). Effects of Nimesulide and Sodium Diclofenac on Interleukin-6, Interleukin-8, Proteoglycans and Prostaglandin E2 Production by Human Articular Chondrocytes in Vitro. Clinical and Experimental Rheumatology, 17 (2), 151-60.

Reginster, J.-Y., Halkin, V., Henrotin, Y., & Gosset, C. (1999). Treatment of Osteoporosis: Role of Bone-Forming Agents. Osteoporosis International, 9 Suppl 2, 91-6. doi:10.1007/PL00004167

Reginster, J.-Y., & Henrotin, Y. (1999). New Therapeutic options. Bone Depeche, 5, 95-101.

Henrotin, Y., Zheng, S. X., Dupont, G., Labasse, A. H., Crielaard, J.-M., & Reginster, J.-Y. (August 1998). Nitric Oxide Downregulates Interleukin 1β (IL-1β) Stimulated IL-6, IL-8, and Prostaglandin E2 Production by Human Chondrocytes. Journal of Rheumatology, 25 (8), 1595-601.

Henrotin, Y., Labasse, A. H., Jaspar, J. M., De Groote, D. D., Zheng, S. X., Guillou, G. B., & Reginster, J.-Y. (1998). Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clinical Rheumatology, 17 (1), 31-9. doi:10.1007/BF01450955

Henrotin, Y., & Reginster, J.-Y. (1998). Le cartilage articulaire peut-il se régénérer ? (2ème partie). Le Généraliste, 415, 11.

Henrotin, Y., & Reginster, J.-Y. (1998). Le cartilage articulaire peut-il se régénérer ? (1ère partie). Le Généraliste, 414, 31.

Henrotin, Y., & Reginster, J.-Y. (1998). Le cartilage articulaire peut-il se régénérer ? Journal du Médecin (Le), 1129, 33.

Bassleer, C., Franchimont, P., Henrotin, Y., Franchimont, N., Geenen, V., & Reginster, J.-Y. (March 1996). Effects of Ipriflavone and Its Metabolites on Human Articular Chondrocytes Cultivated in Clusters. Osteoarthritis and Cartilage, 4, 1-8. doi:10.1016/S1063-4584(96)80002-1

Henrotin, Y., De Groote, D. D., Labasse, A. H., Gaspar, S. E., Zheng, S. X., Geenen, V., & Reginster, J.-Y. (1996). Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis and Cartilage, 4 (3), 163-73. doi:10.1016/S1063-4584(96)80012-4

Henrotin, Y., Labasse, A., Jaspar, J., De Groote, D., Zheng, S., & Reginster, J.-Y. (1996). Is IL-6 capable to modify chondrocyte metabolism ? Clinical Rheumatology, 15, 539.

Henrotin, Y., De Groote, D., Labasse, A., Deby, C., Geenen, V., & Reginster, J.-Y. (1995). Cytokines and cartilage degradation. Mediators of Inflammation, 4, 229-230.

Henrotin, Y., Franchimont, P., & Reginster, J.-Y. (1995). Interactions between IL-1bêta, IL-6, IL-8 and LIF produced by human chondrocytes. The Official EULAR Journal for Education and Information, 24, 134.

Henrotin, Y., Deby-Dupont, G., DEBY, C., De Bruyn, M., Lamy, M., & FRANCHIMONT, P. (1993). Production of active oxygen species by isolated human chondrocytes. British Journal of Rheumatology, 32 (7), 562-7. doi:10.1093/rheumatology/32.7.562

Henrotin, Y., Bassleer, C., & Franchimont, P. (July 1992). In Vitro Effects of Etodolac and Acetylsalicylic Acid on Human Chondrocyte Metabolism. Agents and Actions, 36 (3-4), 317-23.

Bassleer, C., Henrotin, Y., & Franchimont, P. (March 1992). Effects of Sodium Naproxen on Differentiated Human Chondrocytes Cultivated in Clusters. Clinical Rheumatology, 11 (1), 60-5. doi:10.1007/BF02207086

Bassleer, C., Henrotin, Y., & Franchimont, P. (1992). In-vitro evaluation of drugs proposed as chondroprotective agents. International Journal of Tissue Reactions, 14 (5), 231-41.

Bassleer, C., Henrotin, Y., Reginster, J.-Y., & Franchimont, P. (1992). Effects of tiaprofenic acid and acethylsalicylic acid on human articular chondrocytes in 3-dimensional culture. Journal of Rheumatology, 19, 1433-1438.

Bassleer, C., Henrotin, Y., & Franchimont, P. (1990). In Vitro Assays of Chondrocyte Functions: The Influence of Drugs and Hormones. Scandinavian Journal of Rheumatology. Supplement, 81, 13-20. doi:10.3109/03009749009096940

Henrotin, Y., Bassleer, C., Collette, J., Nusgens, B., & Franchimont, P. (1990). Radioimmunoassay for Human Type Ii Collagen. Journal of Immunoassay, 11 (4), 555-578. doi:10.1080/01971529008055050

Franchimont, P., Bassleer, C., & Henrotin, Y. (August 1989). Effects of Hormones and Drugs on Cartilage Repair. Journal of Rheumatology. Supplement, 18, 5-9.

Franchimont, P., Bassleer, C., Henrotin, Y., Gysen, P., & Bassleer, R. (August 1989). Effects of Human and Salmon Calcitonin on Human Articular Chondrocytes Cultivated in Clusters. Journal of Clinical Endocrinology and Metabolism, 69 (2), 259-66. doi:10.1210/jcem-69-2-259

Henrotin, Y., Bassleer, C., Reginster, J.-Y., & Franchimont, P. (March 1989). Effects of Etodolac on Human Chondrocytes Cultivated in Three Dimensional Culture. Clinical Rheumatology, 8 (Suppl 1), 36-42. doi:10.1007/BF02214108

Henrotin, Y., Sanchez, C., De Pauw, E., & Mazzucchelli, G. (30 January 2019). OSTEOMODULIN AND OSTEOMODULIN FRAGMENTS AS BIOMARKERS FOR OSTEOARTHRITIS AND USE THEREOF.

Henrotin, Y., Sanchez, C., De Pauw, E., & Mazzucchelli, G. (27 September 2017). Osteomodulin and osteomodulin fragments as biomarkers for osteoarthritis and use thereof.

Henrotin, Y., Sanchez, C., De Pauw, E., & Mazzucchelli, G. (25 September 2017). Osteomodulin and osteomodulin fragments as biomarkers for osteoarthritis and use thereof.

Henrotin, Y., Lambert, C., Borderie, D., & Rannou, F. (23 June 2016). Coll2-1 peptide and its nitrated form as therapeutic targets for osteoarthritis treatment.

Henrotin, Y., Gharbi, M., DEBERG, M., & De Pauw, E. (20 January 2016). Biomarker for osteoarthritis and use thereof.

Serisier, S., Comblain, F., & Henrotin, Y. (20 November 2014). Joint care composition.

Henrotin, Y., Sanchez, C., Oprenyeszk, F., & Drion, P. (18 November 2014). Intra-articularly supplementation method for treating joint diseases and injuries.

Henrotin, Y., Kesteloot, F., & Sanchez, C. (11 November 2014). Cell cultivation in chitosan alginate hydrogel beads.

Henrotin, Y., Gharbi, M., DEBERG, M., & De Pauw, E. (08 July 2014). Biomarker for osteoarthritis and/or other ageing-related diseases, and use thereof.

Henrotin, Y., Sanchez, C., Oprenyeszk, F., & Drion, P. (02 January 2013). An intra-articular supplement for use in treating joint diseases and injuries.

REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (11 December 2012). Detection of specific nitrated markers.

Henrotin, Y., Kesteloot, F., & Sanchez, C. (01 September 2011). CELL CULTIVATION IN CHITOSAN ALGINATE HYDROGEL BEADS.

Henrotin, Y., Sanchez, C., Oprenyeszk, F., & Drion, P. (01 September 2011). An intra-articular supplementation method for treating joint diseases and injuries.

Henrotin, Y., Kesteloot, F., & Sanchez, C. (31 August 2011). Cell cultivation in chitosan alginate hydrogel beads.

Reginster, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (29 March 2011). Detection of specific nitrated markers.

Henrotin, Y., Gharbi, M., Deberg, M., & De Pauw, E. (23 March 2011). BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF.

Henrotin, Y., Gharbi, M., Deberg, M., & De Pauw, E. (23 February 2011). BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF.

Reginster, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (01 June 2010). Method for monitoring collagen type II degradation in cartilage.

Henrotin, Y., Gharbi, M., Deberg, M., & De Pauw, E. (09 December 2009). Biomarker for osteoarthritis and/or other ageing-related diseases, and use thereof.

REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (12 August 2008). Method for monitoring collagen type II degradation in cartilage.

REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (01 July 2008). Detection of specific nitrated markers.

Reginster, J.-Y., Deberg, M., Henrotin, Y., & Christgau, S. (22 December 2004). DETECTION OF SPECIFIC NITRATED MARKERS.

Reginster, J.-Y., Deberg, M., Henrotin, Y., & Christgau, S. (15 December 2004). METHOD FOR MONITORING COLLAGEN TYPE II DEGRADATION IN CARTILAGE.

Henrotin, Y. (04 December 2015). Les marqueurs biologiques de l'arthrose : de la découverte à l'industrialisation [Paper presentation]. Université de Nantes, Nantes, France.

Henrotin, Y. (10 March 1991). Traitement kinésithérapique de l'arthrose [Paper presentation]. Conférence organisée par le cercle des licenciés en kinesithérapie de l'université de Liège, Liège, Belgium.